Is Broach Lifecare overvalued or undervalued?

As of 19 September 2025, the valuation grade for Broach Lifecare has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently undervalued, with a PE ratio of 10.93, an EV to EBITDA ratio of 11.78, and a Price to Book Value of 1.18. These ratios suggest that Broach Lifecare is trading at a discount compared to its peers, particularly when considering that Apollo Hospitals has a PE ratio of 71.29 and an EV to EBITDA of 36.65, while Max Healthcare is categorized as very expensive with a PE of 93.83.
In comparison to its industry peers, Broach Lifecare stands out as a more attractive investment opportunity, especially given its PEG ratio of 0.00, which indicates no growth premium is being paid for its earnings. Despite recent stock performance showing a decline of 25.38% over the past year compared to a slight increase in the Sensex, the underlying financial metrics suggest that Broach Lifecare is well-positioned for potential recovery and growth, reinforcing its undervaluation status.